August 2025 in “American Journal of Clinical Dermatology” Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
August 2025 in “Frontiers in Immunology” People with alopecia areata have a higher risk of heart disease.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
March 2025 in “International Journal of AYUSH Case Reports” Individualized homeopathy may help treat alopecia areata.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
January 2025 in “Advances in Dermatology and Allergology” The Polish version of the Alopecia Areata Quality of Life Index is a reliable tool for assessing quality of life in Polish-speaking patients with alopecia areata.
January 2025 in “Universidad de Córdoba Insitutional Repository (Universidad de Córdoba)” An imbalanced scalp microbiome may worsen alopecia areata severity and inflammation, but treatment can partially restore balance.
November 2024 in “Journal of Young Pharmacists” Siddha medicine helped a child regrow hair lost from alopecia areata.
October 2024 in “Revista Electronica de Veterinaria” Siddha medicine can effectively treat Alopecia areata, leading to significant hair regrowth.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
August 2024 in “OSMANGAZİ JOURNAL OF MEDICINE” The visfatin GT genotype may increase the risk of Alopecia Areata.
July 2024 in “Egyptian Journal of Medical Human Genetics” These gene variations are not linked to alopecia areata in Egyptians.
Four genes are linked to alopecia areata, with two increasing risk and two offering protection.
April 2024 in “Research Square” IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
April 2024 in “Dermatology and therapy” In Denmark from 1995 to 2016, hospital-treated alopecia areata cases increased, mostly affecting women and those over 50.
March 2024 in “Journal of Natural Remedies” An 18-year-old with hair loss saw hair regrowth after treatments combining microneedling, cupping, medication, and oil application.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
February 2024 in “Scientific reports” Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.
February 2024 in “Sohag Medical Journal” Various local treatments for alopecia areata show promise, but individualized plans and more research are needed.
February 2024 in “Journal of ayurveda and integrated medical sciences” Ayurvedic treatments helped a 16-year-old regrow hair after modern medicine failed.
January 2024 in “Dermatology practical & conceptual” Atopic dermatitis in kids with alopecia areata can predict poor response to topical immunotherapy.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
January 2024 in “Archives of dermatological research” Both treatments for alopecia areata showed similar modest effectiveness.
January 2024 in “International Journal of Homoeopathic Sciences” Individualized homeopathic treatment can effectively treat alopecia areata.
January 2024 in “Annals of Dermatology” DPCP immunotherapy is effective for alopecia areata, and understanding influencing factors can improve treatment and satisfaction.
January 2024 in “Annals of Dermatology” Current treatments for Alopecia Areata don't fully meet patients' needs, indicating a need for better therapies.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.